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Abstract 
Homozygotic spasmodic (spdlspd) mice suffer from a motor disorder resembling poisoning by the glycine receptor antagonist strychnine. Here, 
a point mutation was identified in the glycine receptor al subunit gene of the spasmodic mouse which predicts an alanine-to-serine exchange at position 
52 of the mature polypeptide. Upon expression in Xenopus Iaevis oocytes, al As2s receptor channels displayed reduced responses to glycine, /I-alanine 
and taurine when compared to recombinant ccl glycine receptors. As glycine receptor content in spinal cord and native molecular weight appeared 
unaltered, this suggests that the spasmodic phenotype results from an altered neurotransmitter sensitivity of the mutant alAszs subunit. 
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1. Introduction 
Neuronal inhibition in spinal cord and brainstem is 
primarily mediated by the amino acid glycine and is 
effectively antagonized by the convulsant alkaloid 
strychnine [1,2]. The inhibitory glycine receptor (GlyR) 
is a ligand-gated chloride channel composed of ligand 
binding a: and structural B subunits which are highly 
homologous to each other [3]. Within the extracellular 
N-terminal domain of the cx subunits, determinants of 
ligand binding [4-81 and sequence motifs crucial for the 
oligomerization of the GlyR complex [9] have been iden- 
tified. Of the four hydrophobic segments (Ml-M4) pre- 
dicted to span the post-synaptic membrane, segment M2 
is thought to form the inner wall of the receptor channel 
[3,10]. Differential expression of distinct variants of the 
ligand binding subunits, CI l-a4 [4,1 l-l 61, contributes to 
a developmental and regional heterogeneity of the GlyR 
[2,17]. The receptor isoform prevailing in adult rodent 
spinal cord, GlyR, [17], is a pentameric assembly of al 
and p subunits [2]. 
As exemplified by sublethal strychnine intoxication, 
GlyR dysfunction results in muscle rigidity and hyperex- 
citability. Inherited phenotypes mimicking strychnine in- 
toxication are found in two strains of mutant mice, spas- 
tic and spasmodic [I 8,191. The spastic (spa) mutation is 
inherited by a recessive gene on chromosome 3 and char- 
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acterized by a dramatic deficit of the adult receptor 
isoform GlyR, [19-211, which results from aberrant 
splicing of the GlyR p subunit pre-mRNA (Miilhardt et 
al., submitted). A motor disorder very similar to the 
spastic phenotype is seen in the spasmodic (spd) mouse, 
an unknown mutation linked to chromosome 11. In con- 
trast to the spastic mutant, however, GlyR ligand bind- 
ing has been reported to be unaltered in the CNS of 
spdlspd mice [22]. Synteny homology exists between the 
mouse chromosome 11 and the human chromosomal 
region 5q2 1 -q3 1 [23,24] which includes the human locus 
of the al subunit gene of the inhibitory GlyR ([25]; 
T. Siddique and H. Betz, personal communication). Based 
on the genetic homology of human and murine chromo- 
somal loci, and the similarity of spastic and spasmodic 
phenotypes, the GlyR oil subunit gene was considered a 
candidate for the spasmodic mutation of the mouse. 
Here, we report a point mutation in the oil subunit gene 
of the spasmodic mouse which predicts an alanine-to- 
serine exchange at position 52 of the mature polypeptide 
sequence and significantly affects agonist responses. 
2. Experimental 
2. I. Animal Care 
Homozygous pdlspd mice were produced by mating tested B6C3Fe- 
ala, spd/+ breeders purchased from the Jackson Laboratory (Bar Har- 
bor, Maine 04609, USA). In contrast to earlier observations [22], an 
intermediate phenotype was present in adult heterozygotic animals 
(spd/+). Age-matched control animals were wild-type mice either of the 
B6C3Fe-ala or the C57BL/6J strain. 
2.2. Protein methods 
Clycine-displaceable binding of [3H]strychnine (16 nM; 29 Ci/mmol; 
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DuPont NEN, Bad Homburg, Germany) to crude membrane fractions 
from spinal cord [17,26] was determined in triplicate by a filtration 
assay employing 80 pug of protein [21]. For radioligand displacement 
assays, membranes were incubated with 16 nM [‘HIstrychnine and 
increasing concentrations of unlabelled ligands. Ligand binding data 
were analyzed using the computer program GraphPad. Monoclonal 
antibody (MAb 4a) was employed for immunodetection of GlyR by 
Western blot (11% acrylamide gel, 80 pg protein per lane) or dot 
immunoassay (8 mg protein/well) [26]. Immunoquantitation was per- 
formed in triplicate and reactivities were corrected for background 
absorbances obtained in the absence of the first antibody. The MAb 
4a antigen content of spdlspd tissue was expressed as the mean + S.E.M. 
of immunoreactivities standardized to paired wild-type samples (n = 3) 
producing specific absorbances of 0.314 + 0.029 dOD, 0.250 + 0.017 
dOD, and 0.286 f 0.013 dOD. For sucrose gradient sedimentation 
analysis of GlyR, 5-20% gradients were centrifuged and subjected to 
immunoassay [26]. Immunohistology of GlyRs was performed as de- 
scribed [27]. 
2.3. Reverse transcriptase-polymerase chain reaction 
Total RNA (2-5 pg) extracted from spinal cord [28] was reverse- 
transcribed into cDNA using the Superscript-Preamplification System 
(Gibco-BRL); appropriate aliquots (= 100 ng of cDNA) were subjected 
to PCR amplification performed in 15 mM Tris, pH 8.3, 2.25 mM 
MgCl,, 50 mM KCI, 100 mM of each dNTP, and 0.2 mM of each 
PCR-primer using Taq DNA Polymerase (Boehringer Mannheim). 
During 34 cycles, conditions were as follows: heating to 95°C for 45 s, 
annealing at 55°C for 60 s, synthesis at 72°C for 90 s. 
2.4. DNA blots and sequencing 
cDNA fragments generated by PCR amplification were electro- 
phoresed on a 1% agarose gel, transferred to a nylon membrane (Zeta- 
Probe GT; Bio-Rad), and hybridized to a random labeled 807 bp cDNA 
fragment comprising nt 253-1060 of the coding sequence of the murine 
al subunit [l6]. Hybridization was in buffer containing 5 x SSC, 5 x 
Denhardt’s, 25 mM Nap,, pH 7.4, I mM NaPP,, lOO~g/ml ssDNA, and 
1% SDS at 65’C. Washings were performed in 2 x SSC, 0.1% SDS at 
65°C. For analysis of genomic DNA samples isolated from the livers 
of two spdhpd and two wild-type mice, PCR amplification was per- 
formed as above, except hat the elongation time was 30 s. After puri- 
fication of genomic or cDNA and subcloning into pBluescript, DNA 
sequences were determined by the chain termination method according 
to standard procedures [29]. The murine al and rxlA52S subunit cDNA 
sequences obtained here differed from those published ([16]; GenBanW 
EMBL Data Bank X7583240) in two non-coding nucleotide positions 
of exon 9 (A-tG at nt position 1275, T-tC at nt position 1287). 
2.5. Oligonucleotide primers 
Oligonucleotides were synthesized on an automated DNA synthe- 
sizer (Applied Biosystems). For amplification of the murine al subunit 
cDNA [I61 the following primers were designed to generate adequate 
restriction-sites flanking the open reading frame: sense, 5’-GCGGATC- 
CATGTACAGCTTCAATACTCTTCGA (SlblB; BarnHI); anti- 
sense, 5’CGATGAATTCTCACTTGTTGTGGACATCCTC (AS9/E; 
EcoRI). DNA fragments encompassing exon 3 and flanking intronic 
sequences of the al subunit gene [16] were amplified from genomic 
DNAs using the primer combination SiZIIB (intron 2, sense, S-CG- 
GATCCAGGCACTTAGGGGTGG; BamHI) and ASi3-I/E (in- 
tron 3, antisense, S-CGAATTCACAGCAGTTGCTGTAACGT- 
ACTC; EcoRI). 
2.6. Heterologous expression of glycine receptors 
GlyR al subunit cDNAs were cloned into a pSP64T-derived vector 
[30] and recombinant full-length plasmids were used to generate syn- 
thetic capped and polyadenylated cRNA employing SP6 polymerase 
(Promega) [29]. Injection of cRNAs into Xenopus laevis oocytes, and 
voltage clamp-recordings, were done as described [3 I]. We found that 
the use of polyadenylated cRNAs resulted in EC,, values of agonist 
responses exceeding those obtained by untailed al and alAs2s subunit 
cRNAs by about an order of magitude (data not shown; compare 
[5,6,31]). Similar increases in affinities have also been observed after 
high-density expression in Xenopus oocytes of al subunit cDNA con- 
structs [32]. 
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3. Results 
Glycine displaceable [3H]strychnine binding to spinal 
cord membranes constitutes a reliable marker of GlyR, 
[2,17,21]. For mutant and wild-type mice, both 
[3H]strychnine binding activity (spdlspd 1379 + 272 fmol/ 
mg; wild-type 1325 + 98 fmol/mg) and affinity (Fig. 1, 
Table 1) were indistinguishable, confirming an earlier 
report [22]. For spdlspd mice, however, we consistently 
obtained = 2-fold lower affinities for displacement of 
[3H]strychnine binding by glycine, /I-alanine and taurine 
(Fig. 1, Table 1). Monoclonal antibody (MAb) 4a defines 
an epitope common to all GlyR 01 subunits [3,17]. When 
spinal cord membranes from spdlspd and wild-type mice 
were subjected to Western blot analysis, MAb 4a de- 
tected a polypeptide of 48 kDa (Fig. 2A) corresponding 
to the previously described al subunit of murine GlyR, 
[19,21]. Upon immunoquantitation by MAb 4a [26], 
membrane samples from spdlspd mice produced 
90.2 + 20.0% of the wild-type signal, indicating similar 
spinal cord contents of GlyR. Moreover, when deter- 
0.01 
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Fig. I. Binding of GlyR ligands to membranes from spinal cord of 
spdlspd (0) and wild-type mice (0). Binding of [‘HIstrychnine (I6 nM) 
was displaced by increasing concentrations of either unlabelled strych- 
nine (upper panel) or glycine (lower panel). Data are means + S.E.M. 
of triplicate determinations of the fractional binding to crude mem- 
branes from either genotype. The 95% confidence intervals of glycine 
displacement were distinct for spdlspd and wild-type samples. 
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gent-solubilized GlyR preparations were subjected to su- 
crose gradient centrifugation, single peaks migrating 
with apparent sedimentation constants of = 7.9 S were 
observed for both genotypes (Fig. 2B). Furthermore, 
immunohistology employing MAb 4a revealed that the 
neuronal localization of GlyRs was unaltered in spinal 
cord of spdlspd mice (not shown). We therefore conclude 
that the spasmodic mutation affects the agonist binding 
properties of GlyR, rather than its native protein struc- 
ture, content, or cellular localization in spinal cord. 
GlyR al subunit transcripts were investigated by PCR 
amplification of cDNA synthesized on spinal cord total 
RNA. A primer combination which covers the entire 
coding region of the al subunit [16] yielded amplification 
products indistinguishable in size (= 1.4 kb) for spdlspd 
and wild-type cDNAs (Fig. 3A). Cloning into 
pBluescript and sequencing of several recombinants 
identified a G-T substitution in nucleotide position 238 
of the cDNA of spdlspd mice (Fig. 3B). This single nucle- 
otide exchange resulted in an amino acid substitution at 
position 52 in the mature alA52S subunit of the spasmodic 
mouse where the alanine residue of the wild-type was 
replaced by a serine residue in the mutant. The cllASzS 
subunit transcripts from spdlspd mice contained a fur- 
ther, however silent, T-+C nucleotide substitution at 
position 198. Both point mutations were located in exon 
3 (Table 2) of the GlyR al subunit [16]. Rodent al 
subunit transcripts comprise two splice variants resulting 
from alternative selection of the splice acceptor site of 
exon 9 [16,33]. Here, cDNAs were obtained from spas- 
modic mouse spinal cord which represented both splice 
variants of the a1A52S subunit (not shown). To confirm 
the oil subunit mutation of the spasmodic mouse at the 
genomic level, genomic DNA fragments encompassing 
exon 3 and neighbouring intronic sequences were ampli- 
fied [16]. Sequence analysis of the 216 bp DNA frag- 
ments generated confirmed both nucleotide substitu- 
tions, indicating that the spasmodic mutation is an allele 
of exon 3 of the murine al subunit gene (Table 2). 
Recombinant expression of the cxl subunit in eukar- 
yotic cells generates GlyR channels resembling the ligand 
pharmacology of native receptors [5,31,34]. Upon injec- 
Table 1 
Affinity constants of GlyR ligand binding to spinal cord membranes 
from +I+ and spdlspd mice 
Ligand Wild-type 
Kl 
spdlspd 
nH K, nH 
[‘HIStrychnine 22.6 + 3.6 nM l.O* 21.72 3.5 nM 1.0: 
Glycine 37.3 f 2.2 PM 1.3 68.1 f 10.9 PM 1.9 
B-Alanine 55.3 f 10.0 PM 1.1 135.7 + 39.7 PM 1.4 
Taurine 152.7 + 7.6 PM 1.7 318.8 f 44.1 PM 1.4 
K,, inhibition constant for displacement of [‘HIstrychnine binding by 
the respective unlabelled ligand [2,21]; nu, Hill coefficient. 
*Assuming a single-site competition, nn for displacement by 
[‘HIstrychnine was defined as 1 .O. 
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Fig. 2. Structural properties of the GlyR protein from wild-type and 
spdlspdmouse spinal cord. (A) Western blot analysis. In crude mem- 
branes from wild-type (+I+) and spdlspd mice, MAb 4a recognizes an 
al polypeptide of = 48 kDa molecular weight. (B) Sedimentation pro- 
file of detergent-solubilized GlyRs as analyzed by MAb 4a. On 5-20% 
sucrose gradients, GlyRs from either genotype migrated at positions 
corresponding to an apparent S value of 7.9. Positions of marker en- 
zyme reactivities (0) were as indicated: (1) j?-galactosidase, 15.95 S; 
(2) catalase, 11.3 S; (3) aldolase, 7.4 S; (4) LDH, 7.0 S; (5) MDH, 4.3 S. 
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Table 2 
Nucleotide and deduced amino acid sequences encoded by exon 3 of rodent GlyR a subunit variants 
al wt GGTCCTCCTGTGAATGTAAGTTGCAACATCTTCATCTTCATC~CAGTTTCGGTTCCATCGCTGAGAC~CCATG (252) 
vd . . . . . . . . . . . . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..T.............. 
wt GPPVNVSCNIFI NSFGSIAE T TM (56) 
vd . . . . . . . . . . . . . . . . . . s . . . . 
a2A . . . . . . T..........VT.... ('j-3 
a2B . . . . . . T . . . . . . . . . . . . . . . . (62) 
a3 . . . . . . T . . . . . . . . . . . . . . . (56) 
a4 . . . . . . T..........VT.... (62) 
The al subunit nucleotide and deduced polypeptide sequences from wild-type mice (wt) and spdlspd mutants (spd) are aligned with rodent a subunit 
variants (murine a2A, a2B, a4; rat a3) [13-161. The first codon is split into exons 2 and 3. Numbering starts with the first nucleotide of the respective 
cDNA coding sequence, and with the N-terminal first amino acid of the mature polypeptide. Identical nucleotides and amino acids are indicated 
by dots. 
tion of synthetic a1A52S subunit cRNA, Xenopus oocytes 
produced glycine-induced inward currents as analyzed 
by voltage-clamp recording (Fig. 4). Using ~11~~~~ cRNA, 
half-maximal currents were observed at concentrations 
(EC,,) of glycine, /I-alanine and taurine which were sig- 
nificantly lower than EC,, values obtained with oil 
cRNA (Fig. 4, Table 3). The currents induced by ~11~~~~ 
and al cRNAs were highly sensitive to strychnine, with 
half-maximal inhibition at antagonist concentrations 
(Table 3) matching affinities derived from radioligand 
binding (Table 1). In oocytes injected with al cRNA, the 
maximum currents elicited by application of either 
p-alanine (I,,,,) or taurine (I,,,) equaled those evoked by 
glycme (Z,,,): ZsalaZZ~lr = 0.95 & 0.04; ZtaulZgly = 0.90 ? 0.08 
(Fig. 4). When al A52S cRNA was injected, however, sat- 
urating concentrations of /I-alanine or taurine produced 
responses of smaller amplitude (Zs,,,lZ,,, = 0.80 ? 0.06; 
Ztau/Zgly = 0.57 + 0.15). This agonist profile is reminiscent 
of recombinant a2 and a3 GlyRs which also exhibit 
lower maximum current responses to these p-amino 
acids [4,5,13,31]. Thus, the spasmodic mutation appears 
to impair functional properties of GlyR,, resulting in a 
dysfunction of glycinergic inhibition. 
4. Discussion 
As an important mediator of neuronal post-synaptic 
inhibition, GlyR,contributes to mammalian motor regu- 
lation [1,35]. Here we report that the al subunit gene, 
which encodes the ligand binding subunit of GlyR, [2,3], 
is mutated in the motor-deficient spasmodic mouse. The 
T 
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G 
F 
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Fig. 3. Analysis of GlyR al subunit transcripts in mouse spinal cord. (A) PCR amplification of al subunit cDNAs from +/+ and spdlspd mice, using 
a primer combination covering the entire coding sequence (exons I through 9). PCR products were identified by Southern blots hybridized with an 
al subunit-specific cDNA probe comprizing exons 4-8 [16]. (B) Nucleotide substitution (G + T) at position 238 of the GlyR al subunit cDNA 
resulting in an amino acid exchange in spdlspd mice. The nucleotide difference between +I+ and spdlspd (arrow) leading to the substitution of alanine 
by serine is revealed by the cDNA sequence (coding strand, gel lanes: G, A, T, C). The amino acid sequences (single letter code) encoded by the two 
DNA ladders and reading from bottom to top are listed next to the gel patterns. 
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Fig. 4. Glycine-elicited membrane currents recorded from Xenopus oocytes injected with al and alA5’s cRNAs. (A) Current responses of oocytes 
injected with the corresponding cRNA and superfused with agonists. Downward deflections denote inward currents recorded at a holding potential 
of -70 mV, horizontal bars = duration of agonist application. (B) Dose-response relationship of glycine-induced inward currents in oocytes injected 
with al (0) and cclA5*s cRNA (0). For both cRNAs, data are normalized to peak amplitudes (I,,,,,) obtained at saturating concentrations of glycine; 
al subunit cRNA I,,, = 1304 f 757 nA; alAszS subunit cRNA I,,,,, = 720 f 173 nM. 
spasmodic mutation produces an alanine-to-serine x- 
change at position 52 of the N-terminal domain of the 
mature al polypeptide, resulting in altered GlyR agonist 
binding and current responses upon recombinant expres- 
sion in Xenopus oocytes. A sequence comparison of 
GlyR a subunit variants reveals that alanine residues are 
conserved at homologous positions in al [I 1,121, a2B 
[14], and a3 [ 131 subunits. In contrast, threonine residues 
are encoded by the a2A splice variant which is highly 
responsive to glycine [ 12,14,15], and the a4 subunit gene 
[ 161. The functional significance of this subunit heteroge- 
neity is not understood. Within the N-terminal domain 
of the al subunit, non-continuous structural motifs are 
involved in ligand binding and discrimination [3]: 
(i) amino acid residues 159-161 comprise determinants 
of agonist and high affinity strychnine binding [4,6,7]; 
(ii) residue 111 is essential for GlyR channel activation 
by taurine [5]; (iii) a /?-sheet-/?-turn motif formed by 
residues 200-212 is thought to contribute to agonist- 
Table 3 
Current responses of al and aAS’s receptor channels generated by 
cRNA expression in Xenopus oocytes 
Ligand al 
ECS~ 
alASZS 
nH EC,, nH 
Glycine 6127 PM 2.4 _+ 0.2 176 f 41 PM 1.8 f 0.1 
/I-Alanine 106f 32 PM 1.8 + 0.1 373 f 163 PM 1.8 + 0.1 
Taurine 757 f 234 PM 2.0 f 0.1 1300 f 284pM 1.9 + 0.1 
Strychnine* 42&S nM - 55 f IO nM - 
EC,, values for agonists were obtained by single sigmoid fits of normal- 
ized agonist-evoked peak currents. Data represent average + S.E.M. of 
3-5 determinations; nu, Hill coefficient. 
*For strychnine, I&, values were determined at glycine concentrations 
producing half-maximal responses. 
antagonist discrimination [7,8]. The spasmodic mutation 
lies outside of these regions and thus defines a new deter- 
minant of agonist-mediated channel activation. As com- 
ponents of a multisubunit protein, a and B polypeptides 
also carry characteristic ‘cassettes’ governing receptor 
assembly [9] which, in the a1A52S subunit, indeed flank 
the site of the mutation, Although single amino acid 
exchanges may interfere with oligomerization of recom- 
binant al polypeptides [lo], no evidence was obtained 
here that the spasmodic mutation alters the native protein 
structure of GlyR,. 
Several lines of evidence indicate that the amino acid 
substitution identified in the a1A52S subunit is causal for 
the spasmodic phenotype: (i) spasmodic symptoms [22] 
mimic states of GlyR dysfunction as encountered in the 
GlyR,-deficient spastic mouse [19-211, or induced by 
sublethal strychnine poisoning [2]; (ii) the functional im- 
pairment of al A52S subunit GlyRs is consistent with a 
loss of glycine-mediated motor inhibition [I]; (iii) the 
spasmodic locus on chromosome 11 [22,24] is linked by 
synteny homology to the human chromosomal region 
5q21-q3 1 [23] where the al subunit gene has been 
mapped [25]. Recently, Shiang et al. [25] identified point 
mutations in the human al subunit gene which cause the 
dominant neurological disorder, hyperekplexia, which 
resembles the spasmodic phenotype. These mutations 
predict amino acid substitutions delineating transmem- 
brane segment M2 [25] which, upon heterologous expres- 
sion, render homomeric al GlyRs functionally inactive 
[lo]. While both, human hyperekplexia and the spas- 
modic mouse are associated with GlyR a 1 subunit muta- 
tions, the predominant expression of this subunit in adult 
rodents [3,17] deviates from the postnatal alleviation of 
hyperekplexia symptoms [25]. Thus, GlyR regulation 
may differ between these species or the phenotype of 
hyperekplexia is effectively attenuated by epigenetic 
76 
mechanisms. Our analysis of the spasmodic mouse cor- 
roborates the functional importance of distinct GlyR 
isoforms and shows that a point mutation affecting 
transmitter sensitivity may provide the molecular basis 
of a neurological disorder. 
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